From: Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience
Diagnosis | Our series | Dickson’s series [[4]] | De la Rosa’s series [[3]] | Lee’s series [[6]] | ||||
---|---|---|---|---|---|---|---|---|
 | N° of cases | P63+ cases (%) | N° of cases | P63+ cases (%) | N° of cases | P63+ cases (%) | N° of cases | P63+ cases (%) |
GCTOB | 5 | 100% | 17 | 100% | 23 | 86.9% | 6 | 81% |
Osteosarcoma | 12 | 8.3% | 0 | - | 4 | 50% | 13 | 15.3% |
Osteoblastoma | 8 | 37.5% | 0 | - | 0 | - | 0 | - |
ABC | 5 | 40% | 7 | 28.6% | 8 | 62.5% | 25 | 20% |
CGCG | 4 | 0% | 12 | 0% | 4 | 100% | 12 | 0% |
NOF | 4 | 25% | 0 | - | 6 | 16.6% | 0 | - |
OO | 4 | 50% | 0 | - | 0 | - | 0 | - |
CMF | 3 | 33.4% | 0 | - | 0 | - | 12 | 0% |
Chondroblastoma | 1 | 100% | 10 | 30% | 12 | 83.3% | 15 | 40% |
FD | 1 | 0% | 0 | - | 2 | 0% | 4 | 0% |
LCH | 1 | 0% | 0 | - | 0 | - | 0 | - |
chondrosarcoma | 0 | - | 0 | - | 0 | - | 0 | - |
Brown tumor | 0 | - | 0 | - | 0 | - | 4 | 0% |